KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Pacira BioSciences (PCRX) over the last 16 years, with Q3 2025 value amounting to -$153.0 million.

  • Pacira BioSciences' Net Cash Flow fell 1396507.35% to -$153.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$98.7 million, marking a year-over-year decrease of 16722.21%. This contributed to the annual value of $123.5 million for FY2024, which is 15117.68% up from last year.
  • Pacira BioSciences' Net Cash Flow amounted to -$153.0 million in Q3 2025, which was down 1396507.35% from $16.7 million recorded in Q2 2025.
  • Pacira BioSciences' Net Cash Flow's 5-year high stood at $451.5 million during Q4 2021, with a 5-year trough of -$358.8 million in Q1 2022.
  • Moreover, its 5-year median value for Net Cash Flow was $12.3 million (2023), whereas its average is $2.5 million.
  • As far as peak fluctuations go, Pacira BioSciences' Net Cash Flow soared by 188566.85% in 2021, and later tumbled by 1396507.35% in 2025.
  • Pacira BioSciences' Net Cash Flow (Quarter) stood at $451.5 million in 2021, then plummeted by 101.17% to -$5.3 million in 2022, then soared by 1125.15% to $54.2 million in 2023, then plummeted by 43.13% to $30.8 million in 2024, then crashed by 596.7% to -$153.0 million in 2025.
  • Its Net Cash Flow stands at -$153.0 million for Q3 2025, versus $16.7 million for Q2 2025 and $6.8 million for Q1 2025.